CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.203
AS - Asia 9.608
EU - Europa 9.497
SA - Sud America 1.437
Continente sconosciuto - Info sul continente non disponibili 390
AF - Africa 279
OC - Oceania 34
Totale 50.448
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.526
SG - Singapore 2.843
GB - Regno Unito 2.705
CN - Cina 1.914
IT - Italia 1.837
HK - Hong Kong 1.296
VN - Vietnam 1.186
BR - Brasile 1.096
DE - Germania 838
FI - Finlandia 738
BD - Bangladesh 725
SE - Svezia 691
IE - Irlanda 448
UA - Ucraina 433
FR - Francia 405
RU - Federazione Russa 396
PL - Polonia 368
TR - Turchia 365
CA - Canada 308
IN - India 257
ID - Indonesia 202
BG - Bulgaria 190
JP - Giappone 121
AR - Argentina 103
IQ - Iraq 102
KR - Corea 94
MX - Messico 83
ES - Italia 62
NL - Olanda 60
EG - Egitto 59
EC - Ecuador 58
PK - Pakistan 56
TT - Trinidad e Tobago 53
MY - Malesia 50
ZA - Sudafrica 50
VE - Venezuela 48
BE - Belgio 46
LT - Lituania 46
CO - Colombia 43
AE - Emirati Arabi Uniti 42
MA - Marocco 40
CR - Costa Rica 39
PH - Filippine 38
CL - Cile 34
JO - Giordania 34
AT - Austria 33
NP - Nepal 33
TW - Taiwan 33
JM - Giamaica 32
UZ - Uzbekistan 31
HN - Honduras 28
TN - Tunisia 27
SA - Arabia Saudita 26
AU - Australia 25
CZ - Repubblica Ceca 25
IL - Israele 23
KE - Kenya 23
SV - El Salvador 23
RO - Romania 22
CH - Svizzera 21
GT - Guatemala 20
PY - Paraguay 20
DZ - Algeria 19
GP - Guadalupe 18
IR - Iran 18
NI - Nicaragua 18
CW - ???statistics.table.value.countryCode.CW??? 17
EU - Europa 17
TH - Thailandia 17
MD - Moldavia 16
PR - Porto Rico 16
DO - Repubblica Dominicana 15
HU - Ungheria 15
PT - Portogallo 15
AZ - Azerbaigian 14
PE - Perù 14
UY - Uruguay 13
SN - Senegal 12
NO - Norvegia 11
KZ - Kazakistan 10
OM - Oman 10
DK - Danimarca 9
AL - Albania 8
EE - Estonia 8
SC - Seychelles 8
SY - Repubblica araba siriana 8
BH - Bahrain 7
ET - Etiopia 7
GH - Ghana 7
NZ - Nuova Zelanda 7
PA - Panama 7
RS - Serbia 7
BO - Bolivia 6
HR - Croazia 6
LB - Libano 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
CY - Cipro 5
GE - Georgia 5
Totale 49.986
Salva come PNG Salva come JPEG
Città #
Ashburn 3.295
Fairfield 3.220
Santa Clara 2.010
Singapore 1.816
Woodbridge 1.805
Southend 1.676
Houston 1.482
Seattle 1.283
Hong Kong 1.271
Chandler 1.184
Cambridge 1.023
Wilmington 1.015
San Jose 1.001
Council Bluffs 805
Jacksonville 753
Dearborn 736
Ann Arbor 731
Helsinki 599
Beijing 554
London 493
Nyköping 468
Dublin 437
Warsaw 355
New York 330
Modena 322
Ho Chi Minh City 310
Los Angeles 308
The Dalles 301
Dallas 276
Hanoi 269
Boardman 261
San Diego 251
Chicago 234
Izmir 219
Princeton 193
Milan 190
Columbus 188
Sofia 186
Lauterbourg 181
Eugene 174
Buffalo 162
Jakarta 158
Hefei 132
Shanghai 116
Moscow 114
Dong Ket 103
São Paulo 102
Tokyo 88
Seoul 84
Falls Church 82
Munich 77
Frankfurt am Main 76
Orem 75
Phoenix 74
North Bergen 72
Rome 66
Salt Lake City 66
Bremen 63
Da Nang 63
Fremont 63
Atlanta 60
Redwood City 57
Toronto 57
Ottawa 56
Baghdad 53
Bologna 49
Saint Augustine 47
Brooklyn 46
Guangzhou 46
Denver 45
Port of Spain 39
Redondo Beach 39
Montreal 38
Mumbai 38
Brussels 37
Miano 36
Naples 36
Newark 36
San Giuliano Milanese 36
Belo Horizonte 34
Tampa 33
Chennai 32
Haiphong 32
San José 32
Des Moines 31
Rio de Janeiro 31
Miami 30
Poplar 30
Brasília 29
Norwalk 29
Philadelphia 29
Tashkent 29
Washington 29
Cairo 28
Amman 27
Mexico City 26
Florence 25
Turku 25
Nuremberg 24
Charlotte 23
Totale 35.500
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 658
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 601
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 483
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 468
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 454
GD2 expression in breast cancer. 449
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 449
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 432
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 421
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 419
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 405
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 401
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 399
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 384
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 384
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 381
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 381
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 380
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 380
The evolving role of microsatellite instability in colorectal cancer: A review 376
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 373
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 372
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 368
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 359
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 358
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 354
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 352
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 351
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 350
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 342
5-Fluorouracil pharmacogenomics: still rocking after all these years? 341
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 335
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 333
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 333
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 332
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 331
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 331
Transient sunitinib resistance in gastrointestinal stromal tumors. 330
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 329
Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming? 328
Il trattamento di prima e seconda linea nel carcinoma gastrico 328
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 327
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 326
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 326
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 326
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 317
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 316
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 315
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 310
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 308
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 305
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 304
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 303
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 302
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 302
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 297
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 297
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 297
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 294
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 294
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 293
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 292
The Italian Rare Pancreatic Exocrine Cancer Initiative 290
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 289
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 286
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 285
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 283
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 276
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 276
Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) 276
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 273
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. 271
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 270
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 270
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 270
Dabrafenib-trametinib combination in 'field-practice': An Italian experience 269
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 267
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 267
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 265
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 263
Bone metastases- Pharmacological treatment 262
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 261
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 261
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 260
BRAF-mutated colorectal cancer: Clinical and molecular insights 260
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 259
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 259
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 257
A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) 256
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 255
Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response 255
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 255
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 254
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 254
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 253
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 252
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 251
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 251
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 251
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 249
Totale 32.447
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.382 0 0 0 0 96 237 184 191 373 348 642 311
2022/20233.538 411 357 221 315 409 418 51 283 766 41 148 118
2023/20242.030 76 115 115 190 417 121 250 346 43 53 95 209
2024/20256.810 273 93 122 455 1.438 1.039 487 457 825 394 413 814
2025/202613.065 678 270 874 1.092 1.539 1.360 1.859 701 1.269 1.139 1.260 1.024
2026/20274.643 530 986 1.059 1.676 392 0 0 0 0 0 0 0
Totale 50.448